Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Dow
Fish and Richardson
AstraZeneca
UBS
Boehringer Ingelheim
Express Scripts
Chinese Patent Office
Chubb

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,572,920

« Back to Dashboard

Summary for Patent: 7,572,920
Title:Benzimidazole derivative and use as a II receptor antagonist
Abstract:The present invention relates to a compound represented by the formula (I) ##STR00001## wherein R.sup.1 is a group represented by the formula ##STR00002## wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently a hydrogen atom or a C.sub.1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like.
Inventor(s): Kuroita; Takanobu (Katano, JP), Sakamoto; Hiroki (Amagasaki, JP), Ojima; Mami (Amagasaki, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/466,633
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,572,920

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION ➤ Sign Up
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION ➤ Sign Up
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION ➤ Sign Up
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-002 Dec 20, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERTENSION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,572,920

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-048928Feb 25, 2004

Non-Orange Book US Patents Family Members for Patent 7,572,920

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,157,584 Benzimidazole derivative and use thereof ➤ Sign Up
7,875,637 Benzimidazole derivative and use as a II receptor antagonist ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,572,920

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2009115498 ➤ Sign Up
Russian Federation 2369608 ➤ Sign Up
Russian Federation 2006133898 ➤ Sign Up
Serbia 52376 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Federal Trade Commission
Julphar
Harvard Business School
Teva
Boehringer Ingelheim
McKinsey
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.